Janmejay Vyas, chairman of the Dishman Group, shares the story of his success in establishing a trustworthy relationship with the strictest drug regulator in the world, the US FDA.
Mr Vyas, since the very beginning your focus has been on research and developing various in-house technologies for quaternary ammonium compounds and APIs. Can you tell our international readers about the main trends occurring in the Indian Contract Research and Manufacturing (CRAM) market?
"While the market size renders India an attractive location for large foreign companies seeking to expand operations, and set up their R&D centers, I believe that the lack of standardization of training across the country plays an important role in preventing companies to do so."
